Cyclosporine is named as an intervention in 5 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is BioRay Pharmaceutical Co., Ltd (2). The most-studied condition is Primary Membranous Nephropathy.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH
NCT05936086 · ClinicalTrials.gov ↗ · Hemophagocytic Syndrome
|
Not applicable | Recruiting | shifeng Lou | China |
|
Evaluation of the Efficacy of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
NCT07830433 · ClinicalTrials.gov ↗ · Primary Membranous Nephropathy
|
Phase 3 | Not yet open | BioRay Pharmaceutical Co., Ltd. | China |
|
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
NCT05303727 · ClinicalTrials.gov ↗ · Neuroblastoma
|
Phase 2 | Not yet open | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | China |
|
A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy
NCT05862233 · ClinicalTrials.gov ↗ · Primary Membranous Nephropathy
|
Phase 3 | Active, closed | Beijing Mabworks Biotech Co., Ltd. | China |
|
A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
NCT06642909 · ClinicalTrials.gov ↗ · Primary Membranous Nephropathy
|
Phase 2 | Active, closed | BioRay Pharmaceutical Co., Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| BioRay Pharmaceutical Co., Ltd. | 2 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Beijing Mabworks Biotech Co., Ltd. | 1 |
| shifeng Lou | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 5 | 1 |
A trial with sites in more than one country appears in each of those registers.
5 current trials in our China register name Cyclosporine as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 5 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
BioRay Pharmaceutical Co., Ltd (2), Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1), Beijing Mabworks Biotech Co., Ltd (1) and shifeng Lou (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cyclosporine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cyclosporine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cyclosporine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.